A recent appellate court decision coupled with a spate of warning letters sets the stage for more class action lawsuits like the proposed ones filed against CBD companies this week, experts say.
An upcoming webinar will explore the taxonomic changes to the genus Lactobacillus and the implications for brands, from labeling to consumer education.
Hemp-derived CBD brands Charlotte’s Web and Infinite Product Co. have both been hit with proposed class action lawsuits filed in California that allege they misled consumers by marketing their products as dietary supplements when FDA has specifically...
A leading nutritionist is calling for greater awareness of vitamin D deficiency in younger healthy populations that are becoming susceptible to an increased diabetes risk as a result.
The UFC Anti-Doping Policy now includes a definition of certified supplements to help athletes steer clear of contaminated substances and recognize the value of third-party supplement certification.
While penning 15 warning letters about CBD in one day (more than the FDA has sent in three years) attracted a lot of media attention, does it signal a change in enforcement priorities for the agency, which has repeatedly warned that cannabidiol is not...
Sparked by proposed US Department of Agriculture regulations that would drastically alter the certification process for industrial hemp, two lawmakers from Oregon want the agency to make several changes before it finalizes rules for the US Domestic Hemp...
The US Food and Drug Administration has stated that it cannot conclude that CBD (cannabidiol) is generally recognized as safe (GRAS) for its use in human food, based on a “lack of scientific information supporting the safety of CBD in food”.
Pressure continues to build to find a resolution to the CBD impasse. A trade organization and a state government have filed notices with FDA on the issue.
Europe’s Food Safety Authority (EFSA) rules scientific evidence pointing to a white kidney bean extract’s link with body weight reduction as “insufficient,” after the applicant cites application process inconsistencies.
The turmoil surrounding the CBD question has obscured other important debates, such as how to alter DHSEA is such a way that more scientific information can be conveyed to consumers.
An expert panel has recommended an expanded treatment envelope for the EPA drug Vascepa. An expert says the move won’t affect the supplement market directly but does add to recent official recognition of the health benefits of omega-3s.
